GLSHQ (Gelesis Holdings) Other Operating Expense: $2.27 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gelesis Holdings Other Operating Expense?

Gelesis Holdings GLSHQ -99.00% Other Operating Expense is $2.27 Mil as of Jun. 2023.

Gelesis Holdings's Other Operating Expense for the three months ended in Jun. 2023 was $0.57 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 was $2.27 Mil.

Gelesis Holdings's quarterly Other Operating Expense declined from Dec. 2022 ($0.57 Mil) to Mar. 2023 ($0.57 Mil) but then increased from Mar. 2023 ($0.57 Mil) to Jun. 2023 ($0.57 Mil).

Gelesis Holdings's annual Other Operating Expense increased from . 20 ($0.00 Mil) to Dec. 2021 ($2.27 Mil) but then stayed the same from Dec. 2021 ($2.27 Mil) to Dec. 2022 ($2.27 Mil).

Gelesis Holdings Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Other Operating Expense Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Other Operating Expense
2.27 2.27

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.57 0.57 0.57 0.57

Gelesis Holdings Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $2.27 Mil mean?
Gelesis Holdings (GLSHQ) has a Other Operating Expense of $2.27 Mil as of Jun. 2023. Other operating expenses that a company records on its income statement. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Other Operating Expense too high?
Gelesis Holdings' current Other Operating Expense is $2.27 Mil.
How does Gelesis Holdings' Other Operating Expense compare to RBSH and PPCB?
Gelesis Holdings' Other Operating Expense of $2.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Other Operating Expense is $2.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Other Operating Expense of $2.27 Mil. The current Other Operating Expense is $2.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Other Operating Expense is $2.27 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.